Business

Dyax Corp. stock gains 7 percent

istockphoto

This is a summary. To read the whole story subscribe to BostonGlobe.com

Burlington-based Dyax Corp. got a higher price target from Needham & Co. analyst Serge Belanger, who reiterated a “buy” rating. The new price target is $13, up from $7.50, thanks to the experimental drug DX2930. “The DYAX story . . . now centers on DX2930, the company’s antibody under development for prophylactic HAE treatment,” Belanger said. He expects favorable study data soon. The drug is for hereditary angioedema, a rare acute inflammatory condition with severe swelling of the extremities, gastrointestinal tract, genitalia, and larynx.

Full story for BostonGlobe.com subscribers.

Get the full story with unlimited access to BostonGlobe.com.

Just 99 cents for four weeks.

Share